Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 02'nd Aug 2024
BRIDGEWATER, N.J. , Aug. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024
08:00am, Monday, 29'th Jul 2024
BRIDGEWATER, N.J. , July 29, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:07am, Thursday, 25'th Jul 2024
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Jul 2024
BRIDGEWATER, N.J. , July 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including F
Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
08:00am, Thursday, 27'th Jun 2024
BRIDGEWATER, N.J. , June 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Top 4 Health Care Stocks That May Keep You Up At Night This Month
08:44am, Tuesday, 11'th Jun 2024
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
3 Biotech Stocks to Monitor Right Now
03:33pm, Monday, 10'th Jun 2024
Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08:00am, Friday, 07'th Jun 2024
BRIDGEWATER, N.J. , June 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
08:00am, Wednesday, 05'th Jun 2024
BRIDGEWATER, N.J. , June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t
Insmed (INSM) CEO on the Company's Current Product Pipeline
04:38pm, Tuesday, 04'th Jun 2024
Insmed (INSM) announced positive topline results from an Aspen Phase 3 study of Brensocatib. Insmed is a biopharmaceutical company that develops therapies for patients with serious and rare diseases.
Insmed to Host Commercial Webinar on June 4, 2024
04:05pm, Thursday, 30'th May 2024
BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
08:00am, Thursday, 30'th May 2024
BRIDGEWATER, N.J. , May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
01:21pm, Wednesday, 29'th May 2024
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
Insmed CEO on lung disease treatment and path forward
06:40pm, Tuesday, 28'th May 2024
Will Lewis, Insmed CEO, joins 'Fast Money' to talk its latest lung disease treatment, growth opportunity and more.
